vs
Side-by-side financial comparison of Maase Inc. (MAAS) and Verastem, Inc. (VSTM). Click either name above to swap in a different company.
Verastem, Inc. is the larger business by last-quarter revenue ($11.2M vs $9.9M, roughly 1.1× Maase Inc.).
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
MAAS vs VSTM — Head-to-Head
Income Statement — Q2 FY2023 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.9M | $11.2M |
| Net Profit | — | $-98.5M |
| Gross Margin | 78.7% | — |
| Operating Margin | -55.9% | -362.2% |
| Net Margin | — | -876.3% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -311.1% |
| EPS (diluted) | — | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $11.2M | ||
| Q2 25 | — | $2.1M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $10.0M | ||
| Q4 22 | $9.9M | — |
| Q3 25 | — | $-98.5M | ||
| Q2 25 | — | $-25.9M | ||
| Q3 24 | — | $-24.0M | ||
| Q2 24 | — | $-8.3M | ||
| Q4 22 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 22 | 78.7% | — |
| Q3 25 | — | -362.2% | ||
| Q2 25 | — | -2047.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -182.8% | ||
| Q4 22 | -55.9% | — |
| Q3 25 | — | -876.3% | ||
| Q2 25 | — | -1213.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -82.6% | ||
| Q4 22 | — | — |
| Q3 25 | — | $-1.35 | ||
| Q2 25 | — | $-0.62 | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.31 | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.9M | $137.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.6M | $-15.5M |
| Total Assets | $47.0M | $176.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $137.7M | ||
| Q2 25 | — | $164.3M | ||
| Q3 24 | — | $113.2M | ||
| Q2 24 | — | $83.4M | ||
| Q4 22 | $10.9M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $40.5M | ||
| Q2 24 | — | $40.3M | ||
| Q4 22 | — | — |
| Q3 25 | — | $-15.5M | ||
| Q2 25 | — | $36.1M | ||
| Q3 24 | — | $11.1M | ||
| Q2 24 | — | $18.9M | ||
| Q4 22 | $31.6M | — |
| Q3 25 | — | $176.9M | ||
| Q2 25 | — | $196.3M | ||
| Q3 24 | — | $126.4M | ||
| Q2 24 | — | $105.7M | ||
| Q4 22 | $47.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | 3.66× | ||
| Q2 24 | — | 2.14× | ||
| Q4 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.2M | $-36.2M |
| Free Cash FlowOCF − Capex | $-18.3M | — |
| FCF MarginFCF / Revenue | -184.4% | — |
| Capex IntensityCapex / Revenue | 1.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-36.2M | ||
| Q2 25 | — | $-32.7M | ||
| Q3 24 | — | $-23.8M | ||
| Q2 24 | — | $-27.6M | ||
| Q4 22 | $-18.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-27.6M | ||
| Q4 22 | $-18.3M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -275.8% | ||
| Q4 22 | -184.4% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q4 22 | 1.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
VSTM
Segment breakdown not available.
